We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » LAWMAKERS WORKING TOWARD COMPROMISE ON BIOTECH FUNDING DISPUTE

LAWMAKERS WORKING TOWARD COMPROMISE ON BIOTECH FUNDING DISPUTE

July 13, 2006

More venture capital-backed biotech firms could become eligible for federal research funding under a compromise being worked out by Senate Republicans.

Sen. Olympia Snowe (R-Maine), the chairwoman of the Small Business and Entrepreneurship Committee, will be working with other Republican lawmakers and the Biotechnology Industry Organization (BIO) to decide how to allow biotech firms with venture capital backing to receive federal funds reserved for small businesses. At issue is R&D funding awarded under the Small Business Administration's Small Business Innovation Research Program (SBIR), which accounts for approximately $2 billion in grants annually.

Companies with more than 49 percent ownership by venture capitalists are currently not eligible for SBIR funds. Biotech companies and lawmakers such as Sen. Kit Bond (R-Mo.) argue that these funds are essential to these companies' competitiveness in the marketplace.

Snowe will work to modify Bond's bill S.1263, which amends the Small Business Act (SBA), to make companies with majority venture capital ownership eligible for the funds. "Hopefully we'll find that middle ground" between allowing more firms with venture capital ownership and making eligibility so broad that the companies that currently do not qualify as small businesses become eligible for the SBIR funds, Snowe said after a July 12 hearing on the bill.

The lawmaker wants to determine how to define an "investor" for the purposes of SBIR and decide whether companies supported by individual or multiple venture capitalists should be allowed to receive these funds. Snowe is hoping to address the issue in her committee by the end of July, with an eye toward reauthorization of the SBA by Oct. 1.

Not receiving these funds would be "a major setback," for the biotech industry, Bond said during the hearing. The biotech industry "is like no other in the world" because of the time and money necessary to get products to market, he added, necessitating supplemental funding.

But critics, including the Small Business Technology Council, argue that these funds are better spent on companies that lack the financial backing of venture capitalists. Modifying the definition of a small business is "a slippery slope" that would push legitimately small businesses out of the running for these funds, Gene Watson, program manager of the Wyoming SBIR/STTR (small business technology transfer) Initiative, said.

However, BIO believes that the program "makes us competitive," Lauren Choi, BIO's director of policy, capital formation and emerging companies, said. It is "critical" that SBIR amendments are included in the SBA reauthorization, she said. (http://www.fdanews.com/did/5_136/)

KEYWORDS FDAnews Drug Daily Bulletin

Upcoming Events

  • 01Feb

    The Future of QMS: Will the Recent Announcement and Delays Have a Global Impact?

  • 08Feb

    Process and Design Validation for Devicemakers: A Deep Dive into Best Practices, Recent Trends and Regulatory Definitions

  • 09Feb

    The Inextricable Link Between Data Integrity and Quality Culture

  • 15Feb

    Advanced Compliance Writing CAPA: Mastering Failure Investigation and Root Cause Analysis

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 22Feb

    Best Practices for Developing and Maintaining a GxP Training Matrix

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • NeuroMetrix Launches DPNCheck 2.0 for Peripheral Neuropathy Screening

  • Syros Gets Fast Track Status for Higher-Risk Myelodysplastic Syndrome Candidate

  • FDA Approves Abbott’s Spinal Cord Stimulation System for Diabetic Peripheral Neuropathy

  • FDA Expands Approval for Merck’s Keytruda in NSCLC

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing